Management of delayed cerebral ischemia after subarachnoid hemorrhage

Table 2 Selected pharmacologic interventions that have been evaluated for DCI prevention^a

Intervention	Effect
Aspirin	No effect on new lesion associated with neurological worsening [103]
Clazosentan	No effect on mortality or vasospasm-related morbidity [5]
Enoxaparin	No effect on DCI or GOS at 3 months [104]
Erythropoietin	Less neurological deficit with cerebral infarct; no difference in mRS or GOS at 6 months [105]
Fludrocortisone	No effect on incidence of cerebral ischemia or independent living [27]
Magnesium	No difference in mRS at 3 months [106]
Methylprednisolone	No effect on neurologic worsening; trend towards better GOS at 6 months [107]
Nicardipine	No effect on neurological worsening or GOS at 3 months [102]
Prophylactic angioplasty	No effect on new neurologic deficits or GOS at 3 months [86]
Prophylactic hypervolemia	No effect on neurologic worsening or GOS at 3 months [69]
Statins	No effect on DCI, death or mRS at 6 months [108]

^aExcluding nimodipine. Only randomized controlled trials are considered. References are either the most recent, most definitive, or most robust trial according to the authors’ opinion
DCI delayed cerebral ischemia, GOS, Glasgow Outcome Scale, mRS modified Rankin Scale

ISSN: 1364-8535